About this Research Topic
The inflammatory microenvironment is an important factor mediating the development and progression of cardiometabolic diseases (CMD). It refers to a complex network of cells and molecules that form in a localized area as a result of an inflammatory response. This environment includes various immune cells, extracellular matrix, growth factors, and other inflammatory mediators, which play a key role in cardiovascular tissue repair, disease development, and treatment response. Studies have shown that the inflammatory microenvironment accelerates the occurrence and progression of CMD through various mechanisms, including proinflammatory cytokines, immune cell infiltration, endothelial dysfunction, oxidative stress, and metabolic disorders. Therefore, in-depth exploration of the specific mechanisms, biomarkers, and potential therapeutic applications of the inflammatory microenvironment in these diseases can not only deepen our understanding of the disease but also provide new targets and strategies for clinical treatment.
Critical areas for further exploration include: the role of inflammatory cells in metabolic cardiovascular diseases, such as the specific roles of different types of immune cells (such as macrophages, T cells, B cells and neutrophils) in metabolic cardiovascular diseases, with a special focus on the role of these cells in arterial plaque formation, myocardial fibrosis and cardiac dysfunction; the role of inflammation-related molecules and signaling pathways in metabolic cardiovascular diseases, including the role of key molecules and signaling pathways in the inflammatory microenvironment. For example, the specific mechanisms of tumor necrosis factor (TNF), interleukin (IL) family, chemokines and their receptors in metabolic cardiovascular diseases. Secondly, how metabolic disorders (such as insulin resistance and hyperlipidemia) exacerbate cardiovascular damage through inflammation-related signaling pathways; the role of biomarkers in the inflammatory microenvironment, including the identification and validation of new biomarkers for early diagnosis and monitoring of disease progression. Discuss the clinical application of inflammatory and metabolic markers in metabolic cardiovascular diseases. At the same time, explore the potential biomarkers in the inflammatory microenvironment explored by multi-omics technology; the treatment strategies for metabolic cardiovascular diseases based on inflammatory mechanisms, including evaluation of the effects and potential mechanisms of existing anti-inflammatory treatments in metabolic cardiovascular diseases, along with exploring emerging therapeutic approaches, such as small molecule inhibitors, immunomodulators and gene therapy for their potential in regulating the inflammatory microenvironment effectively.
This research topic aims to collect and publish a series of cutting-edge research on the role of inflammatory microenvironment in metabolic cardiovascular diseases, highlighting the main findings and latest progress in this field. The objective is to expand research directions, enrich the body of knowledge, and explore potential therapeutic applications within the field of metabolic cardiovascular disease research.
We welcome submissions on the following topics, but are not limited to:
- Biological mechanisms of the development of metabolic cardiovascular disease mediated by inflammatory microenvironment, including the exploration of inflammatory mechanisms and their interrelationships in diseases such as atherosclerosis, atrial fibrillation and heart failure.
- Application of inflammation-related biomarkers in the diagnosis of cardiovascular disease, including the relationship between adipose tissue and metabolic cardiovascular disease under inflammatory microenvironment.
- Interaction between inflammatory microenvironment and metabolic disorders, including how metabolic disorders such as insulin resistance and hyperlipidemia aggravate cardiovascular disease through inflammatory mechanisms.
- Clinical application of anti-inflammatory therapy in metabolic cardiovascular disease, including methods for the targeted effects of anti-inflammatory drugs in cardiovascular disease, and evaluation of the efficacy and safety of various anti-inflammatory drugs in the treatment of metabolic cardiovascular disease.
Critical areas for further exploration include: the role of inflammatory cells in metabolic cardiovascular diseases, such as the specific roles of different types of immune cells (such as macrophages, T cells, B cells and neutrophils) in metabolic cardiovascular diseases, with a special focus on the role of these cells in arterial plaque formation, myocardial fibrosis and cardiac dysfunction; the role of inflammation-related molecules and signaling pathways in metabolic cardiovascular diseases, including the role of key molecules and signaling pathways in the inflammatory microenvironment. For example, the specific mechanisms of tumor necrosis factor (TNF), interleukin (IL) family, chemokines and their receptors in metabolic cardiovascular diseases. Secondly, how metabolic disorders (such as insulin resistance and hyperlipidemia) exacerbate cardiovascular damage through inflammation-related signaling pathways; the role of biomarkers in the inflammatory microenvironment, including the identification and validation of new biomarkers for early diagnosis and monitoring of disease progression. Discuss the clinical application of inflammatory and metabolic markers in metabolic cardiovascular diseases. At the same time, explore the potential biomarkers in the inflammatory microenvironment explored by multi-omics technology; the treatment strategies for metabolic cardiovascular diseases based on inflammatory mechanisms, including evaluation of the effects and potential mechanisms of existing anti-inflammatory treatments in metabolic cardiovascular diseases, along with exploring emerging therapeutic approaches, such as small molecule inhibitors, immunomodulators and gene therapy for their potential in regulating the inflammatory microenvironment effectively.
This research topic aims to collect and publish a series of cutting-edge research on the role of inflammatory microenvironment in metabolic cardiovascular diseases, highlighting the main findings and latest progress in this field. The objective is to expand research directions, enrich the body of knowledge, and explore potential therapeutic applications within the field of metabolic cardiovascular disease research.
We welcome submissions on the following topics, but are not limited to:
- Biological mechanisms of the development of metabolic cardiovascular disease mediated by inflammatory microenvironment, including the exploration of inflammatory mechanisms and their interrelationships in diseases such as atherosclerosis, atrial fibrillation and heart failure.
- Application of inflammation-related biomarkers in the diagnosis of cardiovascular disease, including the relationship between adipose tissue and metabolic cardiovascular disease under inflammatory microenvironment.
- Interaction between inflammatory microenvironment and metabolic disorders, including how metabolic disorders such as insulin resistance and hyperlipidemia aggravate cardiovascular disease through inflammatory mechanisms.
- Clinical application of anti-inflammatory therapy in metabolic cardiovascular disease, including methods for the targeted effects of anti-inflammatory drugs in cardiovascular disease, and evaluation of the efficacy and safety of various anti-inflammatory drugs in the treatment of metabolic cardiovascular disease.
Keywords: inflammation, metabolic cardiovascular disease, mechanisms, biomarkers, therapeutic implications
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
